Timing of Initiating Glycopeptide Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: The Impact on Clinical Outcome

Table 4

Multivariate analysis of risk factors for 14-day mortality.

Variable	P-value	OR (95% CI)
Overall mortality
Diabetes mellitus	0.03	1.97 (1.06–3.68)
Nosocomial acquisition	0.17	1.71 (0.80–3.69)
Catheter-related infection	0.05	0.13 (0.02–0.99)
Pneumonia	<0.01	3.95 (1.98–7.91)
APACHE II score > 15	0.04	2.24 (1.02–4.89)
Timing of initiating glycopeptide therapy
Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO Growth	0.40	1.37 (0.66–2.84)
Infection-related mortality
Catheter-related infection	0.16	0.23 (0.03–1.78)
Pneumonia	<0.01	4.47 (2.09–9.58)
APACHE II score > 15	0.02	2.81 (1.19–6.65)
Timing of initiating glycopeptide therapy
Before preliminary BC report indicated SLO growth and within 24 h after BC indicated SLO Growth	0.90	0.95 (0.41–2.21)

BC: blood culture; MRSA: methicillin-resistant S. aureus; SLO: Staphylococcus-like organism.